These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34327853)

  • 21. Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function.
    McCullough PA; Barnard D; Clare R; Ellis SJ; Fleg JL; Fonarow GC; Franklin BA; Kilpatrick RD; Kitzman DW; O'Connor CM; Piña IL; Thadani U; Thohan V; Whellan DJ;
    Clin Cardiol; 2013 Oct; 36(10):611-20. PubMed ID: 23929781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
    Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
    [No Abstract]   [Full Text] [Related]  

  • 23. Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
    Lee YH; Lin PL; Chiou WR; Huang JL; Lin WY; Liao CT; Chung FP; Liang HW; Hsu CY; Chang HY
    ESC Heart Fail; 2021 Apr; 8(2):1204-1215. PubMed ID: 33410280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
    Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Implications of Functional Mitral Regurgitation Severity in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF).
    Naser N
    Med Arch; 2022 Feb; 76(1):17-22. PubMed ID: 35422569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics and outcomes of heart failure with recovered left ventricular ejection fraction.
    Zhang X; Sun Y; Zhang Y; Chen F; Dai M; Si J; Yang J; Li X; Li J; Xia Y; Tse G; Liu Y
    ESC Heart Fail; 2021 Dec; 8(6):5383-5391. PubMed ID: 34569712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
    Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
    Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Ivabradine on Left Ventricular Diastolic Function, Exercise Tolerance and Quality of Life in Patients With Heart Failure: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
    Koroma TR; Samura SK; Cheng Y; Tang M
    Cardiol Res; 2020 Feb; 11(1):40-49. PubMed ID: 32095195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.
    Böhm M; Komajda M; Borer JS; Ford I; Maack C; Tavazzi L; Moyne A; Swedberg K;
    Eur J Heart Fail; 2018 Feb; 20(2):373-381. PubMed ID: 29027329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis.
    Hartmann C; Bosch NL; de Aragão Miguita L; Tierie E; Zytinski L; Baena CP
    Int J Clin Pharm; 2018 Dec; 40(6):1443-1453. PubMed ID: 30173307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure.
    Bonnet D; Berger F; Jokinen E; Kantor PF; Daubeney PEF
    J Am Coll Cardiol; 2017 Sep; 70(10):1262-1272. PubMed ID: 28859790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Characteristics and Outcomes of Patients with Heart Failure and Reduced Ejection Fraction: The Eligibility of Novel Heart Failure Medications.
    Fong MC; Chang HY; Wang CC; Feng AN; Lin WS; Wu YW; Sung SH; Huang JL; Kuo JY; Yin WH
    Acta Cardiol Sin; 2021 Jul; 37(4):394-403. PubMed ID: 34257489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial.
    Mentz RJ; DeVore AD; Tasissa G; Heitner JF; Piña IL; Lala A; Cole RT; Lanfear DD; Patel CB; Ginwalla M; Old W; Salacata AS; Bigelow R; Fonarow GC; Hernandez AF
    Am Heart J; 2020 May; 223():98-105. PubMed ID: 32217365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
    Chioncel O; Lainscak M; Seferovic PM; Anker SD; Crespo-Leiro MG; Harjola VP; Parissis J; Laroche C; Piepoli MF; Fonseca C; Mebazaa A; Lund L; Ambrosio GA; Coats AJ; Ferrari R; Ruschitzka F; Maggioni AP; Filippatos G
    Eur J Heart Fail; 2017 Dec; 19(12):1574-1585. PubMed ID: 28386917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The midrange left ventricular ejection fraction (LVEF) is associated with higher all-cause mortality during the 1-year follow-up compared to preserved LVEF among real-world patients with acute heart failure: a single-center propensity score-matched analysis.
    Borovac JA; Novak K; Bozic J; Glavas D
    Heart Vessels; 2019 Feb; 34(2):268-278. PubMed ID: 30159656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with angiotensin receptor neprilysin inhibitor for Taiwan heart failure patients: Rationale and baseline characteristics of the TAROT-HF study.
    Lin WY; Chung FP; Liao CT; Huang JL; Liang HW; Lee YH; Lin PL; Chiou WR; Hsu CY; Chang HY
    J Chin Med Assoc; 2021 Sep; 84(9):833-841. PubMed ID: 34524212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
    Fudim M; Sayeed S; Xu H; Matsouaka RA; Heidenreich PA; Velazquez EJ; Yancy CW; Fonarow GC; Hernandez AF; DeVore AD
    Circ Heart Fail; 2020 Apr; 13(4):e006645. PubMed ID: 32248695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ARNI in HFrEF-One-Centre Experience in the Era before the 2021 ESC HF Recommendations.
    Niemiec R; Morawska I; Stec M; Kuczmik W; Swinarew AS; Stanula A; Mizia-Stec K
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in blood pressure riser pattern in patients with acute heart failure with reduced mid-range and preserved ejection fraction.
    Ueda T; Kawakami R; Nakada Y; Nakano T; Nakagawa H; Matsui M; Nishida T; Onoue K; Soeda T; Okayama S; Watanabe M; Okura H; Saito Y
    ESC Heart Fail; 2019 Oct; 6(5):1057-1067. PubMed ID: 31325235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.